BEONE MEDICINES LTD. (ONC) FY2026 Q1 P&L / Income Statement

BEONE MEDICINES LTD. (ONC) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product Name by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,513,438,000 US dollars

Cost of revenue (calculated)

167,215,000 US dollars

Gross profit

1,346,223,000 US dollars

Operating expenses (calculated)

1,096,321,000 US dollars

Income from operations

249,902,000 US dollars

Other income (expense), net (calculated)

9,313,000 US dollars

Income before income taxes

259,215,000 US dollars

Income tax expense

31,858,000 US dollars

Net income

227,357,000 US dollars

BLINCYTO - Product revenue, net

34,035,000 US dollars

BRUKINSA - Product revenue, net

1,094,843,000 US dollars

KYPROLIS - Product revenue, net

16,971,000 US dollars

Other - Product revenue, net

33,192,000 US dollars

POBEVCY - Product revenue, net

12,127,000 US dollars

TEVIMBRA - Product revenue, net

206,241,000 US dollars

XGEVA - Product revenue, net

89,920,000 US dollars

Undisclosed (calculated)

26,109,000 US dollars

Cost of sales - product

167,215,000 US dollars

Selling, general and administrative

555,097,000 US dollars

Research and development

541,224,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.